Global HER2 ADC Drugs for Cancer market size is predicted to grow from US$ 7625 million in 2025 to US$ 13720 million in 2032; it is expected to grow at a CAGR of 8.5% from 2026 to 2032.

Global HER2 ADC Drugs for Cancer Market Trends, Growth | CAGR Of 8.5%

The global HER2 ADC Drugs for Cancer market size is predicted to grow from US$ 7625 million in 2025 to US$ 13720 million in 2032; it is expected to grow at a CAGR of 8.5% from 2026 to 2032. In 2025, global HER2 ADC Drugs for Cancer reached approximately 7.27 M Units, with an average global market price of around 1071 USD per Unit. HER2 ADC Drugs for Cancer (HER2-targeted antibody?drug conjugates) are a class of targeted cancer medicines that use an anti-HER2 monoclonal antibody to recognize and bind tumor cells with HER2 overexpression, amplification, or certain HER2-driven biology, and then deliver a highly potent cytotoxic payload into (and sometimes around) those cells. Structurally, they are built from three essential parts: (1) the HER2 antibody (the ?homing? component), (2) a chemical linker (designed to be stable in blood but release the payload under specific conditions), and (3) the payload (a cell-killing drug such as a microtubule inhibitor or topoisomerase I inhibitor). After binding HER2, the ADC is typically internalized and processed so the payload can be released to damage critical cellular machinery and trigger cancer cell death; depending on the payload/linker properties, some HER2 ADCs can also produce a bystander effect, meaning the released payload may diffuse to kill nearby tumor cells that have lower HER2 expression. HER2 ADC Drugs for Cancer fuse the validated targeting precision of anti-HER2 antibodies with the tumor-killing power of highly potent payloads, offering a pragmatic way to overcome two persistent oncology pain points at once: the limited durability of benefit from many standard targeted agents once resistance emerges, and the systemic toxicity that often constrains conventional chemotherapy. By using HER2 as a delivery address, these conjugates can concentrate cytotoxic exposure inside cancer cells and?depending on linker and payload design?extend activity into heterogeneous tumors through bystander killing, which is increasingly important as clinicians recognize that clinically meaningful HER2 biology exists beyond the classic ?HER2-positive? bucket. Looking forward, the category?s market potential is supported by broad applicability across major solid tumors, steady innovation that improves therapeutic index through smarter linkers, controlled conjugation, and next-generation payloads, and the likelihood that HER2 ADCs will become central ?backbone? options that can be sequenced with, or paired alongside, endocrine therapy, immunotherapy, and other targeted agents?positioning the space for sustained expansion without relying on unrealistic expectations. The core raw materials for HER2 ADC Drugs for Cancer mainly include anti-HER2 antibodies, linkers, and auxiliary materials. Typical suppliers include Roche, Daiichi Sankyo, Merck, Thermo Fisher, etc. The downstream applications are mainly in the treatment of diseases such as breast cancer. The production capacity of HER2 ADC Drugs for Cancer varies greatly depending on the antibody production, conjugation process, quality control, and supply chain support. The gross profit margin of HER2 ADC Drugs for Cancer is in the range of 70%-80%. United States market for HER2 ADC Drugs for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. China market for HER2 ADC Drugs for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. Europe market for HER2 ADC Drugs for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. Global key HER2 ADC Drugs for Cancer players cover Roche, AstraZeneca, Daiichi Sankyo, Remegen, Jiangsu Hengrui Medicine, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025. Infinity Market Research newest research report, the ?HER2 ADC Drugs for Cancer Industry Forecast? looks at past sales and reviews total world HER2 ADC Drugs for Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected HER2 ADC Drugs for Cancer sales for 2026 through 2032. With HER2 ADC Drugs for Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world HER2 ADC Drugs for Cancer industry. This Insight Report provides a comprehensive analysis of the global HER2 ADC Drugs for Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on HER2 ADC Drugs for Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global HER2 ADC Drugs for Cancer market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HER2 ADC Drugs for Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HER2 ADC Drugs for Cancer. This report presents a comprehensive overview, market shares, and growth opportunities of HER2 ADC Drugs for Cancer market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Trastuzumab Type &nbsp;&nbsp;&nbsp; Non-trastuzumab Type &nbsp;&nbsp;&nbsp; Segmentation by HER2 Expression Level: &nbsp;&nbsp;&nbsp; HER2 Positive &nbsp;&nbsp;&nbsp; HER2 Low Expression &nbsp;&nbsp;&nbsp; Segmentation by Antibody: &nbsp;&nbsp;&nbsp; Monoclonal Antibody &nbsp;&nbsp;&nbsp; Bispecific Antibody &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Breast Cancer &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Roche &nbsp;&nbsp;&nbsp; AstraZeneca &nbsp;&nbsp;&nbsp; Daiichi Sankyo &nbsp;&nbsp;&nbsp; Remegen &nbsp;&nbsp;&nbsp; Jiangsu Hengrui Medicine &nbsp;&nbsp;&nbsp; Shanghai Henlius Biotech &nbsp;&nbsp;&nbsp; Sichuan Kelun-Biotech Biopharmaceutical Key Questions Addressed in this Report What is the 10-year outlook for the global HER2 ADC Drugs for Cancer market? What factors are driving HER2 ADC Drugs for Cancer market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do HER2 ADC Drugs for Cancer market opportunities vary by end market size? How does HER2 ADC Drugs for Cancer break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global HER2 ADC Drugs for Cancer Annual Sales 2021-2032 &nbsp;2.1.2 World Current & Future Analysis for HER2 ADC Drugs for Cancer by Geographic Region, 2021, 2025 & 2032 &nbsp;2.1.3 World Current & Future Analysis for HER2 ADC Drugs for Cancer by Country/Region, 2021, 2025 & 2032 &nbsp;2.2 HER2 ADC Drugs for Cancer Segment by Type &nbsp;2.2.1 Trastuzumab Type &nbsp;2.2.2 Non-trastuzumab Type &nbsp;2.2.3 HER2 ADC Drugs for Cancer Sales by Type &nbsp;2.2.3.1 Global HER2 ADC Drugs for Cancer Sales Market Share by Type (2021-2026) &nbsp;2.2.3.2 Global HER2 ADC Drugs for Cancer Revenue and Market Share by Type (2021-2026) &nbsp;2.2.3.3 Global HER2 ADC Drugs for Cancer Sale Price by Type (2021-2026) &nbsp;2.3 HER2 ADC Drugs for Cancer Segment by HER2 Expression Level &nbsp;2.3.1 HER2 Positive &nbsp;2.3.2 HER2 Low Expression &nbsp;2.3.3 HER2 ADC Drugs for Cancer Sales by HER2 Expression Level &nbsp;2.3.3.1 Global HER2 ADC Drugs for Cancer Sales Market Share by HER2 Expression Level (2021-2026) &nbsp;2.3.3.2 Global HER2 ADC Drugs for Cancer Revenue and Market Share by HER2 Expression Level (2021-2026) &nbsp;2.3.3.3 Global HER2 ADC Drugs for Cancer Sale Price by HER2 Expression Level (2021-2026) &nbsp;2.4 HER2 ADC Drugs for Cancer Segment by Antibody &nbsp;2.4.1 Monoclonal Antibody &nbsp;2.4.2 Bispecific Antibody &nbsp;2.4.3 Others &nbsp;2.4.4 HER2 ADC Drugs for Cancer Sales by Antibody &nbsp;2.4.4.1 Global HER2 ADC Drugs for Cancer Sales Market Share by Antibody (2021-2026) &nbsp;2.4.4.2 Global HER2 ADC Drugs for Cancer Revenue and Market Share by Antibody (2021-2026) &nbsp;2.4.4.3 Global HER2 ADC Drugs for Cancer Sale Price by Antibody (2021-2026) &nbsp;2.5 HER2 ADC Drugs for Cancer Segment by Application &nbsp;2.5.1 Breast Cancer &nbsp;2.5.2 Others &nbsp;2.5.3 HER2 ADC Drugs for Cancer Sales by Application &nbsp;2.5.3.1 Global HER2 ADC Drugs for Cancer Sale Market Share by Application (2021-2026) &nbsp;2.5.3.2 Global HER2 ADC Drugs for Cancer Revenue and Market Share by Application (2021-2026) &nbsp;2.5.3.3 Global HER2 ADC Drugs for Cancer Sale Price by Application (2021-2026) 3 Global by Company &nbsp;3.1 Global HER2 ADC Drugs for Cancer Breakdown Data by Company &nbsp;3.1.1 Global HER2 ADC Drugs for Cancer Annual Sales by Company (2021-2026) &nbsp;3.1.2 Global HER2 ADC Drugs for Cancer Sales Market Share by Company (2021-2026) &nbsp;3.2 Global HER2 ADC Drugs for Cancer Annual Revenue by Company (2021-2026) &nbsp;3.2.1 Global HER2 ADC Drugs for Cancer Revenue by Company (2021-2026) &nbsp;3.2.2 Global HER2 ADC Drugs for Cancer Revenue Market Share by Company (2021-2026) &nbsp;3.3 Global HER2 ADC Drugs for Cancer Sale Price by Company &nbsp;3.4 Key Manufacturers HER2 ADC Drugs for Cancer Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers HER2 ADC Drugs for Cancer Product Location Distribution &nbsp;3.4.2 Players HER2 ADC Drugs for Cancer Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for HER2 ADC Drugs for Cancer by Geographic Region &nbsp;4.1 World Historic HER2 ADC Drugs for Cancer Market Size by Geographic Region (2021-2026) &nbsp;4.1.1 Global HER2 ADC Drugs for Cancer Annual Sales by Geographic Region (2021-2026) &nbsp;4.1.2 Global HER2 ADC Drugs for Cancer Annual Revenue by Geographic Region (2021-2026) &nbsp;4.2 World Historic HER2 ADC Drugs for Cancer Market Size by Country/Region (2021-2026) &nbsp;4.2.1 Global HER2 ADC Drugs for Cancer Annual Sales by Country/Region (2021-2026) &nbsp;4.2.2 Global HER2 ADC Drugs for Cancer Annual Revenue by Country/Region (2021-2026) &nbsp;4.3 Americas HER2 ADC Drugs for Cancer Sales Growth &nbsp;4.4 APAC HER2 ADC Drugs for Cancer Sales Growth &nbsp;4.5 Europe HER2 ADC Drugs for Cancer Sales Growth &nbsp;4.6 Middle East & Africa HER2 ADC Drugs for Cancer Sales Growth 5 Americas &nbsp;5.1 Americas HER2 ADC Drugs for Cancer Sales by Country &nbsp;5.1.1 Americas HER2 ADC Drugs for Cancer Sales by Country (2021-2026) &nbsp;5.1.2 Americas HER2 ADC Drugs for Cancer Revenue by Country (2021-2026) &nbsp;5.2 Americas HER2 ADC Drugs for Cancer Sales by Type (2021-2026) &nbsp;5.3 Americas HER2 ADC Drugs for Cancer Sales by Application (2021-2026) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC HER2 ADC Drugs for Cancer Sales by Region &nbsp;6.1.1 APAC HER2 ADC Drugs for Cancer Sales by Region (2021-2026) &nbsp;6.1.2 APAC HER2 ADC Drugs for Cancer Revenue by Region (2021-2026) &nbsp;6.2 APAC HER2 ADC Drugs for Cancer Sales by Type (2021-2026) &nbsp;6.3 APAC HER2 ADC Drugs for Cancer Sales by Application (2021-2026) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe HER2 ADC Drugs for Cancer by Country &nbsp;7.1.1 Europe HER2 ADC Drugs for Cancer Sales by Country (2021-2026) &nbsp;7.1.2 Europe HER2 ADC Drugs for Cancer Revenue by Country (2021-2026) &nbsp;7.2 Europe HER2 ADC Drugs for Cancer Sales by Type (2021-2026) &nbsp;7.3 Europe HER2 ADC Drugs for Cancer Sales by Application (2021-2026) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa HER2 ADC Drugs for Cancer by Country &nbsp;8.1.1 Middle East & Africa HER2 ADC Drugs for Cancer Sales by Country (2021-2026) &nbsp;8.1.2 Middle East & Africa HER2 ADC Drugs for Cancer Revenue by Country (2021-2026) &nbsp;8.2 Middle East & Africa HER2 ADC Drugs for Cancer Sales by Type (2021-2026) &nbsp;8.3 Middle East & Africa HER2 ADC Drugs for Cancer Sales by Application (2021-2026) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of HER2 ADC Drugs for Cancer &nbsp;10.3 Manufacturing Process Analysis of HER2 ADC Drugs for Cancer &nbsp;10.4 Industry Chain Structure of HER2 ADC Drugs for Cancer 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 HER2 ADC Drugs for Cancer Distributors &nbsp;11.3 HER2 ADC Drugs for Cancer Customer 12 World Forecast Review for HER2 ADC Drugs for Cancer by Geographic Region &nbsp;12.1 Global HER2 ADC Drugs for Cancer Market Size Forecast by Region &nbsp;12.1.1 Global HER2 ADC Drugs for Cancer Forecast by Region (2027-2032) &nbsp;12.1.2 Global HER2 ADC Drugs for Cancer Annual Revenue Forecast by Region (2027-2032) &nbsp;12.2 Americas Forecast by Country (2027-2032) &nbsp;12.3 APAC Forecast by Region (2027-2032) &nbsp;12.4 Europe Forecast by Country (2027-2032) &nbsp;12.5 Middle East & Africa Forecast by Country (2027-2032) &nbsp;12.6 Global HER2 ADC Drugs for Cancer Forecast by Type (2027-2032) &nbsp;12.7 Global HER2 ADC Drugs for Cancer Forecast by Application (2027-2032) 13 Key Players Analysis &nbsp;13.1 Roche &nbsp;13.1.1 Roche Company Information &nbsp;13.1.2 Roche HER2 ADC Drugs for Cancer Product Portfolios and Specifications &nbsp;13.1.3 Roche HER2 ADC Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.1.4 Roche Main Business Overview &nbsp;13.1.5 Roche Latest Developments &nbsp;13.2 AstraZeneca &nbsp;13.2.1 AstraZeneca Company Information &nbsp;13.2.2 AstraZeneca HER2 ADC Drugs for Cancer Product Portfolios and Specifications &nbsp;13.2.3 AstraZeneca HER2 ADC Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.2.4 AstraZeneca Main Business Overview &nbsp;13.2.5 AstraZeneca Latest Developments &nbsp;13.3 Daiichi Sankyo &nbsp;13.3.1 Daiichi Sankyo Company Information &nbsp;13.3.2 Daiichi Sankyo HER2 ADC Drugs for Cancer Product Portfolios and Specifications &nbsp;13.3.3 Daiichi Sankyo HER2 ADC Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.3.4 Daiichi Sankyo Main Business Overview &nbsp;13.3.5 Daiichi Sankyo Latest Developments &nbsp;13.4 Remegen &nbsp;13.4.1 Remegen Company Information &nbsp;13.4.2 Remegen HER2 ADC Drugs for Cancer Product Portfolios and Specifications &nbsp;13.4.3 Remegen HER2 ADC Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.4.4 Remegen Main Business Overview &nbsp;13.4.5 Remegen Latest Developments &nbsp;13.5 Jiangsu Hengrui Medicine &nbsp;13.5.1 Jiangsu Hengrui Medicine Company Information &nbsp;13.5.2 Jiangsu Hengrui Medicine HER2 ADC Drugs for Cancer Product Portfolios and Specifications &nbsp;13.5.3 Jiangsu Hengrui Medicine HER2 ADC Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.5.4 Jiangsu Hengrui Medicine Main Business Overview &nbsp;13.5.5 Jiangsu Hengrui Medicine Latest Developments &nbsp;13.6 Shanghai Henlius Biotech &nbsp;13.6.1 Shanghai Henlius Biotech Company Information &nbsp;13.6.2 Shanghai Henlius Biotech HER2 ADC Drugs for Cancer Product Portfolios and Specifications &nbsp;13.6.3 Shanghai Henlius Biotech HER2 ADC Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.6.4 Shanghai Henlius Biotech Main Business Overview &nbsp;13.6.5 Shanghai Henlius Biotech Latest Developments &nbsp;13.7 Sichuan Kelun-Biotech Biopharmaceutical &nbsp;13.7.1 Sichuan Kelun-Biotech Biopharmaceutical Company Information &nbsp;13.7.2 Sichuan Kelun-Biotech Biopharmaceutical HER2 ADC Drugs for Cancer Product Portfolios and Specifications &nbsp;13.7.3 Sichuan Kelun-Biotech Biopharmaceutical HER2 ADC Drugs for Cancer Sales, Revenue, Price and Gross Margin (2021-2026) &nbsp;13.7.4 Sichuan Kelun-Biotech Biopharmaceutical Main Business Overview &nbsp;13.7.5 Sichuan Kelun-Biotech Biopharmaceutical Latest Developments 14 Research Findings and Conclusion

Report	Global HER2 ADC Drugs for Cancer Market Size, Share and Analysis Report 2026-2032
Selected License	Multi ID: ILR5302

Buyer Information

Order Summary